International Small-Mid Cap Fund Q1 2026 Performance and Market Review
Finance

International Small-Mid Cap Fund Q1 2026 Performance and Market Review

authorBy Morgan Housel
DateApr 29, 2026
Read time3 min

In the first quarter of 2026, the global small- and mid-capitalization stock market, as evaluated by the MSCI All Country World Ex USA Small Mid Cap Index, experienced a modest increase of 0.35%. However, the Virtus KAR International Small-Mid Cap Fund faced a significant decline, recording a -6.32% return and thus underperforming its benchmark. This period was characterized by persistent AI-driven market dynamics. Noteworthy events included VAT Group's strong performance, fueled by robust demand in the semiconductor equipment sector, and FinecoBank's underperformance, which was affected by concerns over artificial intelligence's potential competitive impact on human advisory services. The fund strategically expanded its portfolio by investing in three new companies: IntegraFin, a software firm based in the UK; Riverstone, a healthcare enterprise from Singapore; and Steadfast Group, an insurance broker operating in Australasia.

During the first three months of 2026, the international small- and mid-cap equity markets demonstrated a slight upward trend, with the benchmark index showing a 0.35% gain. This growth was largely influenced by the ongoing momentum generated by artificial intelligence advancements. The Virtus KAR International Small-Mid Cap Fund, however, did not participate in this positive movement, posting a negative return of 6.32%. This underperformance highlighted a divergence between the fund's strategy and broader market trends. The market's enthusiasm for AI continued to bolster sectors related to technological innovation.

A notable event within the fund's portfolio was the strong showing of VAT Group. This company, benefiting from the robust demand for semiconductor equipment, saw its shares increase significantly, contributing positively to the fund's holdings despite the overall negative performance. Conversely, FinecoBank experienced a downturn. This was primarily attributed to growing anxieties among investors regarding the potential disruption that AI software could bring to human-led financial advisory services, leading to competitive pressures across the global financial sector.

In a strategic move to adjust and diversify its investments, the Virtus KAR International Small-Mid Cap Fund made several new acquisitions during the quarter. These included IntegraFin, a software company based in the United Kingdom, recognized for its technological solutions in the financial services industry. The fund also invested in Riverstone, a healthcare provider from Singapore, indicating a focus on the burgeoning healthcare sector in Asia. Furthermore, the acquisition of Steadfast Group, an insurance brokerage firm operating in Australasia, demonstrated an interest in expanding its presence in the insurance market in that region.

The first quarter of 2026 presented a mixed landscape for international small- and mid-cap investments. While the overall market saw a modest rise, the Virtus KAR International Small-Mid Cap Fund's considerable underperformance prompts a closer examination of its investment decisions and market exposures. The contrasting fortunes of VAT Group and FinecoBank underscore the dual impact of technological advancements, both as a catalyst for growth and a source of competitive pressure. The new additions to the fund's portfolio reflect an adaptive investment approach, aiming to capitalize on opportunities in diverse sectors and geographical markets.

More Articles
Finance
Eli Lilly's Foundayo Poised to Disrupt Oral GLP-1 Market, Challenging Wegovy's Dominance
Eli Lilly has received FDA approval for Foundayo, an oral GLP-1 medication, positioning it as a major competitor to Novo Nordisk's Wegovy. While Foundayo's initial revenue projections are lower than Wegovy's, it is expected to narrow the gap as competition intensifies. This new development marks a significant shift in the obesity treatment landscape, promising increased options and market dynamics for patients and investors alike.
By Robert KiyosakiApr 29, 2026
Finance
Ares Capital: Strong Performance Despite SaaS Loan Concerns
Ares Capital (ARCC) faces market skepticism due to private credit concerns, particularly around SaaS loans. However, ARCC maintains a solid 10% dividend yield, fully supported by net investment income, and boasts a high-quality loan portfolio. Q1'26 saw continued portfolio growth of 9% year-over-year, with a low non-accrual ratio of 1.2%, highlighting diligent underwriting practices. Despite the broader market's anxieties regarding SaaS debt, ARCC's financial health and balance sheet strength remain robust, leading to a 'Hold' recommendation for income-focused investors.
By Fareed ZakariaApr 29, 2026
Finance
Columbia Disciplined Value Fund Outperforms Benchmark in Q1 2026
The Columbia Disciplined Value Fund's Institutional Class shares delivered a 2.27% return in the first quarter of 2026, surpassing the Russell 1000 Value Index's 2.10%. This outperformance was primarily driven by strong stock selection in the energy, healthcare, and materials sectors, despite a broader market loss for U.S. equities due to private credit disruptions and AI concerns. The energy sector, in particular, benefited from rising crude oil prices and investor shifts towards companies with substantial physical assets.
By Mariana MazzucatoApr 29, 2026
Finance
Calamos Global Convertible Fund: Q1 2026 Performance Analysis
The Calamos Global Convertible Fund (CXGCX) mirrored broader market trends in Q1 2026, ending the quarter with a modest 0.50% return. This period saw substantial global convertible issuance, totaling $53.3 billion, highlighting investor interest in this asset class. Notably, Lumentum Holdings Inc. experienced significant gains due to its strategic position in the AI and cloud data center expansion. The portfolio maintains a cautious stance on Europe, reflecting ongoing macro-economic challenges and regulatory hurdles that impact company growth.
By David RubensteinApr 29, 2026
Finance
Oxford Lane Capital Corporation: Reconsidering OXLCN's Position Amidst Market Shifts
Oxford Lane Capital Corporation (OXLC) is a prominent CLO equity CEF. This analysis focuses on OXLCN, its 7.125% term preferred stock, which is currently trading near its par value with a 7.28% current yield and a 7.8% yield to maturity. Given these factors, we are downgrading OXLCN to 'Hold', recommending new purchases only if the price drops closer to $24 per share. Newer OXLC preferred shares offer more attractive coupons, enhancing their resilience during market downturns compared to OXLCN.
By Michele FerreroApr 29, 2026